Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 5

Polycythemia Vera: Choosing the Right Treatment

, , , ,

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

EP. 1: Diagnosing Polycythemia Vera (PV)
EP. 2: Polycythemia Vera: Assessing Risk and Genetic Testing
EP. 3: Polycythemia Vera: Treatment Goals and Options
EP. 4: REVEAL Study: Clinical Implications
Now Viewing
EP. 5: Polycythemia Vera: Choosing the Right Treatment
EP. 6: MAJIC-PV: Clinical Implications in PV
EP. 7: Role of Transplant in Myelofibrosis
EP. 8: Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023
EP. 9: Treating Patients with Myelofibrosis and Anemia
EP. 10: Monitoring Patients on Myelofibrosis Treatment
EP. 11: Future of PV: Unmet Needs
EP. 12: Combination Therapies for MF Management
EP. 13: Future of MF

Related Content:

Polycythemia Vera and Myelofibrosis: Current and Future Standards of CareMyeloproliferative NeoplasmsHematologic Oncology
NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies
Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in in Newly-Diagnosed PV
OncLive’s October Roundup of Key FDA Approvals in Oncology